Bile Duct Cancer Drug Market - Global Industry Analysis

Bile Duct Cancer Drug Market by Type (5-fluorouracil (5-FU), Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin, and Others) and by Application (Hospitals, Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024

Published Date: 07-Jan-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3702 Status : Published

Global bile duct cancer drug market expected to generate revenue of around USD 262 million by 2024, at a CAGR of around 6.6% between 2018 and 2024. The major growth driver of the global bile duct cancer drug market is the increase in the prevalence of bile duct cancer patients across the globe.

Description

The report covers a forecast and an analysis of the bile duct cancer drug market on a global and regional level. The study provides historical data for 2015, 2016, and 2017 along with a forecast from 2018 to 2024 based on revenue (USD million). The study includes drivers and restraints for the bile duct cancer drug market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the bile duct cancer drug market on a global level.

In order to give the users of this report a comprehensive view of the bile duct cancer drug market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Bile Duct Cancer Drug Market

The report provides company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis. 

The study provides a decisive view on the bile duct cancer drug market by segmenting the market based on type, application, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024.

By type, bile duct cancer drug market is segmented as 5-fluorouracil (5-FU), capecitabine, gemcitabine, oxaliplatin, cisplatin, and other. Based on application, bile duct cancer drug market has been segmented into hospitals, clinics, and others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S., Germany, Italy, France, UK, China, Japan, India, and Brazil.

Some key players of the bile duct cancer drug market include Delcath Systems Inc., Accord Healthcare, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly and Company, Mylan N.V, Fresenius Kabi AG, Intercept Pharmaceuticals, Inc., and Celgene Corporation, among others.

This report segments the global bile duct cancer drug market into:

Global Bile Duct Cancer Drug Market: By Product

  • 5-fluorouracil (5-FU)
  • Gemcitabine
  • Cisplatin
  • Capecitabine
  • Oxaliplatin
  • Others

Global Bile Duct Cancer Drug Market: By Application

  • Hospitals
  • Clinics
  • Others

Global Bile Duct Cancer Drug Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Bile Duct Cancer Drug Market, 2017 - 2024 (USD Million)
    • 2.2. Global Bile Duct Cancer Drug Market: Snapshot
  •  
  • Chapter 3. Bile Duct Cancer Drug Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Bile Duct Cancer Drug Market drivers: Impact analysis
      • 3.2.2. The worldwide growing prevalence of bile duct cancer
      • 3.2.3. Technological improvement in the health care sector
    • 3.3. Market Restraints
      • 3.3.1. High-cost cancer treatment in the developed region as well as the high cost associated with clinical trials
      • 3.3.2. long duration in approvals of drug
    • 3.4. Opportunities
      • 3.4.1. An increasing prevalence of cancer and the need for combination therapies
    • 3.5. Porter's Five Forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. The threat from new entrants
      • 3.5.4. The threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Type
      • 3.6.2. Market attractiveness analysis, by Application
      • 3.6.3. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Bile Duct Cancer Drug Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Bile Duct Cancer Drug Market: company market share, 2017
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. Research and Development, and Regional Expansion
  •  
  • Chapter 5. Global Bile Duct Cancer Drug Market - Type Analysis
    • 5.1. Global Bile Duct Cancer Drug Market: Type overview
      • 5.1.1. Global Bile Duct Cancer Drug Market revenue share, by Type, 2017 and 2024(USD Million)
    • 5.2. 5-fluorouracil (5-FU)
      • 5.2.1. Global 5-fluorouracil (5-FU)market, 2017 - 2024(USD Million)
    • 5.3. Gemcitabine
      • 5.3.1. Global Gemcitabine market, 2017 - 2024(USD Million)
    • 5.4. Cisplatin
      • 5.4.1. Global Cisplatin market, 2017 - 2024(USD Million)
    • 5.5. Capecitabine
      • 5.5.1. Global Capecitabine market, 2017 - 2024(USD Million)
    • 5.6. Oxaliplatin
      • 5.6.1. Global Oxaliplatin market, 2017 - 2024(USD Million)
    • 5.7. Others
      • 5.7.1. Global Others market, 2017 - 2024(USD Million)
  •  
  • Chapter 6. Global Bile Duct Cancer Drug Market - Application Analysis
    • 6.1. Global Bile Duct Cancer Drug Market: Application overview
      • 6.1.1. Global Bile Duct Cancer Drug Market revenue share, by Application, 2017 and 2024(USD Million)
    • 6.2. Hospitals
      • 6.2.1. Global Bile Duct Cancer Drug Market for Hospitals, 2017 - 2024(USD Million)
    • 6.3. Clinics
      • 6.3.1. Global Bile Duct Cancer Drug Market for Clinics, 2017 - 2024(USD Million)
    • 6.4. Others
      • 6.4.1. Global Bile Duct Cancer Drug Market for Others, 2017 - 2024(USD Million)
  •  
  • Chapter 7. Global Bile Duct Cancer Drug Market - Regional Analysis
    • 7.1. Global Bile Duct Cancer Drug Market: Regional overview
      • 7.1.1. Global Bile Duct Cancer Drug Market revenue share, by Region, 2015 and 2024
    • 7.2. North America
      • 7.2.1. North America Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
      • 7.2.2. North America Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
        • 7.2.2.1. The U.S.
          • 7.2.2.1.1. The U.S. Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
          • 7.2.2.1.2. The U.S. Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
        • 7.2.2.2. Rest of North America
          • 7.2.2.2.1. Rest of North America Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
          • 7.2.2.2.2. Rest of North America Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
    • 7.3. Europe
      • 7.3.1. Europe Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
      • 7.3.2. Europe Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.3.3. Germany
        • 7.3.3.1. Germany Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.3.3.2. Germany Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.3.4. U.K.
        • 7.3.4.1. U.K. Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.3.4.2. U.K. Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.3.5. France
        • 7.3.5.1. France Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.3.5.2. France Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.3.6. Rest of Europe
        • 7.3.6.1. Rest of Europe Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.3.6.2. Rest of Europe Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
      • 7.4.2. Asia Pacific Bile Duct Cancer Drug Market revenue, Application, 2017 - 2024(USD Million)
      • 7.4.3. China
        • 7.4.3.1. China Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.4.3.2. China Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.4.4. Japan
        • 7.4.4.1. Japan Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.4.4.2. Japan Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.4.5. India
        • 7.4.5.1. India Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.4.5.2. India Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.4.6. Rest of Asia Pacific
        • 7.4.6.1. Rest of Asia Pacific Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.4.6.2. Rest of Asia Pacific Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
      • 7.5.2. Latin America Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.5.3.2. Brazil Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.5.4. Rest of Latin America
        • 7.5.4.1. Rest of Latin America Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.5.4.2. Rest of Latin America Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
      • 7.6.2. The Middle East and Africa Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
  •  
  • Chapter 8. Company Profile
    • 8.1. Delcath Systems Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Therapy portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Accord Healthcare
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Therapy portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. F. Hoffmann-La Roche Ltd.
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Therapy portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Pfizer Inc.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Therapy portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Teva Pharmaceutical Industries Ltd.
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Therapy portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Bristol-Myers Squibb Company
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Therapy portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Eli Lilly and Company
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Therapy portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Mylan N.V.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Therapy portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Fresenius Kabi AG
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Therapy portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments
    • 8.10. Intercept Pharmaceuticals, Inc.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Therapy portfolio
      • 8.10.4. Business strategy
      • 8.10.5. Recent developments

Table Of Figures

List of Figures 

1. Market research process
2. Market research methodology
3. Global Bile Duct Cancer Drug Market revenue, 2017 – 2024 (USD Million) 
4. Porter’s Five Forces Analysis
5. Bile Duct Cancer Drug Market attractiveness analysis, by Type 
6. Bile Duct Cancer Drug Market attractiveness analysis, by Application 
7. Bile Duct Cancer Drug Market: Market attractiveness analysis, by region
8. Company market share analysis, 2015
9. Global Bile Duct Cancer Drug Market revenue share by Type, 2017 and 2024
10. Global Bile Duct Cancer Drug Market, 2017 – 2024 (USD Million)
a. Global 5-fluorouracil (5-FU)market, 2017 – 2024(USD Million)
b. Global Gemcitabine market, 2017 – 2024(USD Million)
c. Global Cisplatin market, 2017 – 2024(USD Million)
d. Global Capecitabine market, 2017 – 2024(USD Million)
e. Global Oxaliplatin market, 2017 – 2024(USD Million)
f. Global Others market, 2017 – 2024(USD Million)
11. Global Bile Duct Cancer Drug Market revenue share by Application, 2017 and 2024
12. Global Bile Duct Cancer Drug Market, 2017 – 2024 (USD Million)
a. Hospitals, 2017 – 2024(USD Million)
b. Clinics, 2017 – 2024(USD Million)
c. Others, 2017 – 2024(USD Million)


Table Of Tables

List of Tables

1. Bile Duct Cancer Drug Market: Market Snapshot                                                                                                                        
2. Drivers of global Bile Duct Cancer Drug Market: Impact analysis 
3. Restraints of Bile Duct Cancer Drug Market: Impact analysis  
4. North America Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million) 
5. North America Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million) 
6. The U.S. Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million) 
7. The U.S. Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million) 
8. Rest of North America Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million) 
9. Rest of North America Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million) 
10. Europe Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million)
11. Europe Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million)
12. Germany Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million)
13. Germany Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million)
14. UK Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million)
15. UK Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million)
16. France Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million) 
17. France Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million) 
18. Rest of Europe Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million)
19. Rest of Europe Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million)
20. Asia Pacific Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million)
21. Asia Pacific Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million)
22. China Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million) 
23. China Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million) 
24. Japan Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million)
25. Japan Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million)
26. India Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million)
27. India Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million)
28. Rest of Asia Pacific Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million) 
29. Rest of Asia Pacific Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million) 
30. Latin America Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million) 
31. Latin America Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million) 
32. Brazil Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million) 
33. Brazil Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million) 
34. Rest of Latin America Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million)
35. Rest of Latin America Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million) 
36. The Middle East and Africa Bile Duct Cancer Drug Market revenue, by Type, 2017 – 2024(USD Million) 
37. The Middle East and Africa Bile Duct Cancer Drug Market revenue, by Application, 2017 – 2024(USD Million)

Methodology

Free Analysis

The bile duct is a thin tube, which starts from the liver ends at the small intestine. The major function of the bile duct is to move bile from gallbladder and liver into the small intestine, where it helps in the digestion of fats present in food. Cancer can affect any part of the bile duct system. This cancer is classified into three types based on the part affected by cancer: perihilar bile duct cancers, intrahepatic bile duct cancers, and distal bile duct cancers. Surgery is the first line of treatment. In the case of inoperable bile duct cancers, radiation therapy, immunotherapy, chemotherapy, targeted therapy, and palliative therapy are used.

The major growth driver of the global bile duct cancer drug market is the increase in the prevalence of bile duct cancer patients across the globe. The increasing prevalence of bile duct cancer is fuelling the demand for treatment. The technological advancement has increased over the period which has led to the development of treatment options. Furthermore, the increase in healthcare expenditure due to increased awareness among people is also expected to promote the growth of bile duct cancer drug market. Moreover, increased research and development activities by various companies to provide affordable treatment for chronic diseases are further fuel the bile duct cancer drug market in the future. The increasing prevalence of cancer and rising demand for combination therapy is further expected to increase the demand for chemotherapy for cancer treatment. However, the high cost of cancer treatment and clinical trials and time-consuming process for the approval of new drugs might inhibit the bile duct cancer drug market over the forecast time period.

Global Bile Duct Cancer Drug Market

The bile duct cancer drug market is classified into type and application. By type, this market is divided into 5-fluorouracil (5-FU), gemcitabine, cisplatin, capecitabine, oxaliplatin, and others. The 5-fluorouracil segment is anticipated to hold the largest market share over the forecast years. By application, this market is segmented into hospitals, clinics, and others. Hospitals are expected to hold the largest market share in the forecast time period. 

By region, North America is projected to lead the global bile duct cancer drug market. Increased prevalence of bile duct cancer, a large number of ongoing research activities, the quicker and easy product approval process, rising number of awareness programs, and growing government and public-private investments in this region are the key factors driving this regional market. The U.S. and Canada are anticipated to nurture the demand for angiography devices, owing to the increased prevalence of bile duct cancer. The Asia Pacific bile duct cancer drug market is expected to grow at the highest CAGR over the forecast time period, owing to increasing cases of risk of liver fluke infections and growing awareness programs, conferences, and funding activities.

Some key players of the bile duct cancer drug market include Delcath Systems Inc., Accord Healthcare, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly and Company, Mylan N.V, Fresenius Kabi AG, Intercept Pharmaceuticals, Inc., and Celgene Corporation, among others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed